TY - JOUR
T1 - Oncologic Outcomes of Intracorporeal italic toggle="yes">vs Extracorporeal Urinary Diversion after Robot-Assisted Radical Cystectomy
T2 - A Multi-Institutional Korean Study
AU - Ham, Won Sik
AU - Rha, Koon Ho
AU - Han, Woong Kyu
AU - Kwon, Tae Gyun
AU - Kim, Tae Hwan
AU - Jeon, Seung Hyun
AU - Lee, Sang Hyup
AU - Kang, Seok Ho
AU - Kang, Sung Gu
AU - Nam, Jong Kil
AU - Kim, Wansuk
AU - Jeong, Byung Chang
AU - Ku, Ja Hyun
AU - Oh, Jong Jin
AU - Lee, Sang Chul
AU - Lee, Ji Yeol
AU - Hong, Sung Hoo
AU - Lee, Young Goo
AU - Lee, Yong Seong
AU - Park, Sung Yul
AU - Yoon, Young Eun
AU - Kim, Jongchan
N1 - Publisher Copyright:
© Copyright 2021, Mary Ann Liebert, Inc., publishers 2021.
PY - 2021/10
Y1 - 2021/10
N2 - Background: We aimed to compare the oncologic outcomes of intracorporeal urinary diversion (ICUD) and extracorporeal urinary diversion (ECUD) following robot-assisted radical cystectomy (RARC) in patients diagnosed with bladder cancer. Materials and Methods: Medical records of 730 patients who underwent RARC between April 2007 and May 2019 in 11 tertiary referral centers were retrospectively reviewed. We assessed recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) in the two groups using the Kaplan-Meier method. Cox regression models were used to identify factors associated with RFS, CSS, and OS. Results: Among 591 patients, neobladder diversion was performed more frequently in the ICUD group (70.8% vs 52.5%, p = 0.001). The median follow-up duration was shorter in the ICUD group than in the ECUD group (16 vs 26 months, p < 0.001). The rates of overall recurrence (36.5% vs 25.5%, p = 0.013) and pelvic recurrence (12.1% vs 5.9%, p = 0.031) were higher in the ECUD group. However, no differences in 5-year RFS (43.2% vs 58.4%, p = 0.516), CSS (79.3% vs 89.7%, p = 0.392), and OS (74.3% vs 81.4%, p = 0.411) were noted between the two groups. Multivariable analysis revealed that when compared to ICUD, ECUD was not associated with RFS (hazard ratio [HR], 0.982; p = 0.920), CSS (HR, 0.568; p = 0.126), and OS (HR, 0.642; p = 0.124). Conclusion: Although there was a difference in recurrence rate between the two groups, multivariable analysis indicated that the diversion technique after RARC did not affect the oncologic outcomes. Large prospective studies with long-term follow-up are warranted to verify the oncologic outcomes of ICUD and ECUD following RARC.
AB - Background: We aimed to compare the oncologic outcomes of intracorporeal urinary diversion (ICUD) and extracorporeal urinary diversion (ECUD) following robot-assisted radical cystectomy (RARC) in patients diagnosed with bladder cancer. Materials and Methods: Medical records of 730 patients who underwent RARC between April 2007 and May 2019 in 11 tertiary referral centers were retrospectively reviewed. We assessed recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) in the two groups using the Kaplan-Meier method. Cox regression models were used to identify factors associated with RFS, CSS, and OS. Results: Among 591 patients, neobladder diversion was performed more frequently in the ICUD group (70.8% vs 52.5%, p = 0.001). The median follow-up duration was shorter in the ICUD group than in the ECUD group (16 vs 26 months, p < 0.001). The rates of overall recurrence (36.5% vs 25.5%, p = 0.013) and pelvic recurrence (12.1% vs 5.9%, p = 0.031) were higher in the ECUD group. However, no differences in 5-year RFS (43.2% vs 58.4%, p = 0.516), CSS (79.3% vs 89.7%, p = 0.392), and OS (74.3% vs 81.4%, p = 0.411) were noted between the two groups. Multivariable analysis revealed that when compared to ICUD, ECUD was not associated with RFS (hazard ratio [HR], 0.982; p = 0.920), CSS (HR, 0.568; p = 0.126), and OS (HR, 0.642; p = 0.124). Conclusion: Although there was a difference in recurrence rate between the two groups, multivariable analysis indicated that the diversion technique after RARC did not affect the oncologic outcomes. Large prospective studies with long-term follow-up are warranted to verify the oncologic outcomes of ICUD and ECUD following RARC.
UR - http://www.scopus.com/inward/record.url?scp=85117163318&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85117163318&partnerID=8YFLogxK
U2 - 10.1089/end.2021.0067
DO - 10.1089/end.2021.0067
M3 - Article
C2 - 33678003
AN - SCOPUS:85117163318
SN - 0892-7790
VL - 35
SP - 1490
EP - 1497
JO - Journal of Endourology
JF - Journal of Endourology
IS - 10
ER -